



Neuroscience Education Institute

# Earn CME credits and review essential prescribing information with our apps!



## NEI LEARN — for your CME needs

- Unlimited CME credits in mental health
- New activities added regularly
- Multiple learning formats

Download for **FREE!**



## NEI PRESCRIBE — for your point-of-care needs

- 140+ psychiatric medications
- Dedicated Child and Adolescent section
- Continuously updated
- Filter to search for alternative medication options

Download for a **FREE 90-day trial!**

# Get these apps today!

*NEI website account (free) required to log in.*



Visit <http://nei-global> to learn more!

<https://doi.org/10.1017/S1092852922000839> Published online by Cambridge University Press



# CNS SPECTRUMS

## CONTENTS

### EDITORIAL

**Professional attitudes toward the use of neuromodulatory technologies in Mexico: Insight for neuroethical considerations of cultural diversity**  
Karen Herrera-Ferrá, Humberto Nicolini, and James Giordano 255

### LETTER TO THE EDITOR

**How concerned should we be about neurotropism of SARS-Cov-2? A brief clinical consideration of the possible psychiatric implications**  
Domenico De Berardis 258

**Unmet needs of mental illness issues in COVID-19: the importance of analyzing neuropsychiatric manifestations**  
Wael Ibrahim 260

### PERSPECTIVES

**Aripiprazole Lauroxil Dosing Regimens: Understanding Dosage Strengths and Injection Intervals**  
Roger W. Sommi, Bhaskar Rege, Angela Wehr, Sejal Faldu, Yangchun Du, and Peter J. Weiden 262

**Galantamine beyond Alzheimer's disease—a fact or artefact?**  
Ahmed Naguy, Khaled Husain, and Bibi Alamiri 268

### REVIEWS

**Eating disorders and autism spectrum: links and risks**  
Barbara Carpita, Dario Muti, Ivan Mirko Cremonese, Andrea Fagiolini, and Liliana Dell'Osso 272

**The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women**  
James G. Pfaus, Amama Sadiq, Carl Spana, and Anita H. Clayton 281

**Use of selective serotonin and norepinephrine reuptake inhibitors (SNRIs) in the treatment of autism spectrum disorder (ASD), comorbid psychiatric disorders and ASD-associated symptoms: a clinical review**  
Muralidhara Shankarapura Nanjappa, Emanuel Voyiaziakis, Basant Pradhan, and Srinagesh Mannekote Thippaiah 290

**Insomnia, sleep loss, and circadian sleep disturbances in mood disorders: a pathway toward neurodegeneration and neuroprogression? A theoretical review**  
Laura Palagini, Pierre A. Geoffroy, Mario Miniati, Giulio Perugi, Giovanni Biggio, Donatella Marazziti, and Dieter Riemann 298

### ORIGINAL RESEARCH

**A single-dose, comparative bioavailability study comparing amphetamine extended-release oral suspension with extended-release mixed amphetamine salts capsules**  
Antonio Pardo, Mohammed Bouhajib, Thomas R. King, Eman Rafla, and Judith C. Kando 309

**Effectiveness of intravenous ketamine in mood disorder patients with a history of neurostimulation**  
Nelson B. Rodrigues, Ashley Siegel, Orly Lipsitz, Danielle S. Cha, Hartej Gill, Flora Nasri, Kevin Simonson, Margarita Shekotikhina, Yena Lee, Mehala Subramaniapillai, Kevin Kratiuk, Kangguang Lin, Roger Ho, Rodrigo B. Mansur, Roger S. McIntyre, and Joshua D. Rosenblat 315

**Does body mass index predict response to intravenous ketamine treatment in adults with major depressive and bipolar disorder? Results from the Canadian Rapid Treatment Center of Excellence**  
Orly Lipsitz, Roger S. McIntyre, Nelson B. Rodrigues, Yena Lee, Hartej Gill, Mehala Subramaniapillai, Kevin Kratiuk, Flora Nasri, Rodrigo B. Mansur, and Joshua D. Rosenblat 322

**The frequency and framing of cognitive lapses in healthy adults**  
Laura McWhirter, Lachlan King, Ellidh McClure, Craig Ritchie, Jon Stone, and Alan Carson 331

**Elevated tau and  $\beta$ -amyloid in the serum of fibromyalgia patients**  
Bich-Hanh Thi Nguy, Wen-Te Liu, Yu-Tai Chang, Chih-Peng Lin, and Jiunn-Horng Kang 339

**Proinflammatory biomarkers are associated with prediabetes in patients with schizophrenia**  
Marco Møller, Simon Fredholm, Mathias E. Jensen, Gitta Wörtwein, Julie R. Larsen, Tina Vilsbøll, Niels Ødum, and Anders Fink-Jensen 347

**Bipolar Spectrum disorders in Parkinson's disease: a systematic evaluation**  
Silvia Bacciardi, Camilla Elefante, Giulio Emilio Brancati, Sonia Mazzucchi, Eleonora Del Prete, Daniela Frosini, Iero Maremmani, Lorenzo Lattanzi, Roberto Ceravolo, Ubaldo Bonuccelli, and Giulio Perugi 355

**Exploring the role of serum lipid profile and neutrophil-to-lymphocyte ratio in violent suicide attempters: a cross sectional study**  
Enrico Capuzzi, Alice Caldiroli, Martina Capellazzi, Ilaria Tagliabue, Annamaria Auxilia, Giulia Ghilardi, Massimiliano Buoli, and Massimo Clerici 362

**Divergence of dose-response with asenapine: a cluster analysis of randomized, double-blind, and placebo control study**  
Yoshiteru Takekita, Shuichi Hiraoka, Yasuhiro Iwama, Naotaka Sunada, Nobuatsu Aoki, Haruhiko Ogata, Toshiya Funatsuki, Chikashi Takano, Tomoyo Yanagida, Yosuke Koshikawa, Minami Naito, Atsuko Yamamoto, Masaki Kato, and Toshihiko Kinoshita 369

**The influence of prescriber and patient gender on the prescription of benzodiazepines: results from the Florida Medicaid Dataset**  
Leanna M. W. Lui, Yena Lee, Orly Lipsitz, Nelson B. Rodrigues, Hartej Gill, Jifeng Ma, Linas Wilkialis, Jocelyn K. Tamura, Ashley Siegel, David Chen-Li, Joshua D. Rosenblat, Rodrigo B. Mansur, Marie A. McPherson, and Roger S. McIntyre 378

## Cambridge Core

For further information about this journal please go to the journal web site at:

**Cambridge.org/cns**



**CAMBRIDGE UNIVERSITY PRESS**